A phase III randomized trial of anastrozole and fulvestrant versus anastrozole or sequential anastrozole and fulvestrant as first-line therapy for postmenopausal women with metastatic breast cancer: Final survival outcomes of SWOG S0226

被引：0
|
作者：
Mehta, Rita S.
Barlow, William E.
Albain, Kathy S.
Vandenberg, Ted A.
Dakhil, Shakher R.
Tirumali, Nagendra L.
Lew, Danika L.
Hayes, Daniel F.
Gralow, Julie R.
Linden, Hannah M.
Livingston, Robert B.
Hortobagyi, Gabriel N.
机构：
[1] UCIMC, Orange, CA USA
[2] SWOG Stat Ctr, Seattle, WA USA
[3] Loyola Univ Chicago, Stritch Sch Med, Maywood, IL USA
[4] London Hlth Sci Ctr, London, ON, Canada
[5] Wichita Community Clin Oncol, Wichita, KS USA
[6] Northwest CCOP Northwest, Portland, OR USA
[7] Univ Michigan, Ann Arbor, MI 48109 USA
[8] Puget Sound Canc Consortium, Seattle, WA USA
[9] Univ Washington, Seattle, WA 98195 USA
[10] Univ Arizona, Arizona Canc, Tucson, AZ USA
[11] MD Anderson, Houston, TX USA
来源：
CANCER RESEARCH | 2018年 / 78卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PD5-07
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Anastrozole versus tamoxifen as first-line therapy in postmenopausal patients with hormone-dependent advanced breast cancer - A prospective, randomized, phase III study
    Milla-Santos, A
    Milla, L
    Portella, J
    Rallo, L
    Pons, M
    Rodes, E
    Casanovas, J
    Puig-Gali, M
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2003, 26 (03): : 317 - 322
  • [22] Anastrozole (Arimidex™) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women:: survival analysis and updated safety results
    Nabholtz, JM
    Bonneterre, J
    Buzdar, A
    Robertson, JFR
    Thürlimann, B
    EUROPEAN JOURNAL OF CANCER, 2003, 39 (12) : 1684 - 1689
  • [23] Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: Results of a North American multicenter randomized trial
    Nabholtz, JM
    Buzdar, A
    Pollak, M
    Harwin, W
    Burton, G
    Mangalik, A
    Steinberg, M
    Webster, A
    von Euler, M
    JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (22) : 3758 - 3767
  • [24] First Results from FACT - An Open-Label, Randomized Phase III Study Investigating Loading Dose of Fulvestrant Combined with Anastrozole Versus Anastrozole at First Relapse in Hormone Receptor Positive Breast Cancer
    Bergh, J.
    Jonsson, P. E.
    Lidbrink, E.
    Trudeau, M.
    Eiermann, W.
    Brattstrom, D.
    Lindemann, J.
    Wiklund, F.
    Henriksson, R.
    CANCER RESEARCH, 2009, 69 (24) : 490S - 491S
  • [25] Efficacy of tamoxifen following anastrozole ('Arimidex') compared with anastrozole following tamoxifen as first-line treatment for advanced breast cancer in postmenopausal women
    Thürlimann, B
    Robertson, JFR
    Nabholtz, JM
    Buzdar, A
    Bonneterre, J
    EUROPEAN JOURNAL OF CANCER, 2003, 39 (16) : 2310 - 2317
  • [26] A randomized trial to assess the biological activity of short-term (pre-surgical) fulvestrant 500 mg plus anastrozole versus fulvestrant 500 mg alone or anastrozole alone on primary breast cancer
    Robertson, John F. R.
    Dixon, J. Michael
    Sibbering, D. Mark
    Jahan, Ali
    Ellis, Ian O.
    Channon, Eddie
    Hyman-Taylor, Pauline
    Nicholson, Robert I.
    Gee, Julia M. W.
    BREAST CANCER RESEARCH, 2013, 15 (02)
  • [27] A randomized trial to assess the biological activity of short-term (pre-surgical) fulvestrant 500 mg plus anastrozole versus fulvestrant 500 mg alone or anastrozole alone on primary breast cancer
    John FR Robertson
    J Michael Dixon
    D Mark Sibbering
    Ali Jahan
    Ian O Ellis
    Eddie Channon
    Pauline Hyman-Taylor
    Robert I Nicholson
    Julia MW Gee
    Breast Cancer Research, 15
  • [28] Cost-effectiveness analysis of fulvestrant versus anastrozole as first-line treatment for hormone receptor-positive advanced breast cancer
    Ding, H.
    Fang, L.
    Xin, W.
    Tong, Y.
    Zhou, Q.
    Huang, P.
    EUROPEAN JOURNAL OF CANCER CARE, 2017, 26 (06)
  • [29] Activity of Fulvestrant 500 mg Versus Anastrozole 1 mg As First-Line Treatment for Advanced Breast Cancer: Results From the FIRST Study
    Robertson, John F. R.
    Llombart-Cussac, Antonio
    Rolski, Janusz
    Feltl, David
    Dewar, John
    Macpherson, Euan
    Lindemann, Justin
    Ellis, Matthew J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (27) : 4530 - 4535
  • [30] A Randomized Trial of Fulvestrant, Everolimus, and Anastrozole for the Front-line Treatment of Patients with Advanced Hormone Receptor-positive Breast Cancer, SWOG S1222
    Moore, Halle C. F.
    Barlow, William E.
    Somlo, George
    Gralow, Julie R.
    Schott, Anne F.
    Hayes, Daniel F.
    Kuhn, Peter
    Hicks, James B.
    Welter, Lisa
    Dy, Philip A.
    Yeon, Christina H.
    Conlin, Alison K.
    Balcueva, Ernie
    Lew, Danika L.
    Tripathy, Debasish
    Pusztai, Lajos
    Hortobagyi, Gabriel N.
    CLINICAL CANCER RESEARCH, 2022, 28 (04) : 611 - 617
12345